EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction

Nicolas C Galinelli iD, Nicholas J Bamford iD, Madison L Erdody, Skye A Mackenzie, Tobias Warnken iD, Patricia A Harris iD, Martin N Sillence iD, Simon R Bailey iD

Equine Veterinary Journal · 2025-11 · 57 (6) · 1612-1622

DOI: 10.1111/evj.14468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Equine Veterinary Journal, online erschienen am 18.02.2025. Verfasst von Nicolas C Galinelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Pergolide, Horse Diseases, Insulin, Pituitary Gland, Intermediate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Research Council, Boehringer Ingelheim, Waltham Centre for Pet Nutrition.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Due to the high frequency of laminitis reported for both conditions, the relationship between pituitary pars intermedia dysfunction (PPID) and insulin dysregulation (ID), and the potential role of dopamine in modifying insulin secretion, requires further investigation.

Objectives

To evaluate the effect of pergolide mesylate on insulin sensitivity and postprandial insulin and glucose responses in horses and ponies with ID, both with or without concurrent PPID. Study design Randomised crossover study.

Methods

Sixteen horses and ponies, comprising eight matched pairs (PPID+ID or ID‐only), were given pergolide mesylate at a dose of 2 μg/kg bwt orally once daily for 4 weeks (plus a 4‐week non‐treatment control period, with a 4‐week washout between phases). A combined glucose and insulin tolerance test (CGIT) and a standard meal test (SMT; containing 1.1 g/kg bwt of starch and 0.1 g/kg bwt of free sugars), were performed before and after each treatment period to determine insulin sensitivity and postprandial insulin and glucose responses, respectively. Variables derived from the CGIT and SMT were analysed using linear mixed models.

Results

Pergolide treatment did not alter any of the variables derived from the CGIT in either the PPID+ID or ID‐only groups (all p > 0.05). For the SMT, insulin responses were reduced by pergolide treatment for the PPID+ID group, with Δ change values for the total area under the curve for insulin over 300 mins (estimated marginal mean [95% confidence interval]) being −25.4 (−39.9 to −7.3) min∙mIU/mL ( p = 0.03) and Δ change values for peak insulin concentration being −100 (−167 to −29) μIU/mL ( p = 0.04). No effect of pergolide treatment was detected for the ID‐only group. Main limitations Number of animals and heterogeneity among groups.

Conclusions

Pergolide had no effect on tissue insulin sensitivity. However, the results suggest that postprandial hyperinsulinaemia may be limited by this dopamine receptor agonist in animals with PPID plus ID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PergolideHorse DiseasesInsulinPituitary Gland, IntermediatePituitary DiseasesDopamine AgonistsAnimalsHorsesCross-Over StudiesMaleFemaleInsulin ResistanceBlood Glucose

Stichwörter der Autor:innen

dopamineendocrinehorsehyperinsulinaemiainsulin resistancelaminitis

Substanzen

PergolideInsulinDopamine AgonistsBlood Glucose

Autor:innen und Institutionen

  • Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
  • Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
  • Equine Studies Group, Waltham Petcare Science Institute, Melton Mowbray, UK.
  • School of Biology and Environmental Science, Queensland University of Technology, Brisbane, Queensland, Australia.

ORCID-Profile: Nicolas C Galinelli, Nicholas J Bamford, Tobias Warnken, Patricia A Harris, Martin N Sillence, Simon R Bailey

Förderung

  • Australian Research Council
  • Boehringer Ingelheim
  • Waltham Centre for Pet Nutrition

Zitieren

APA

Galinelli, N. C., Bamford, N. J., Erdody, M. L., Mackenzie, S. A., Warnken, T., Harris, P. A., Sillence, M. N., & Bailey, S. R. (2025). Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction. Equine Veterinary Journal, 57(6), 1612-1622. https://doi.org/10.1111/evj.14468

Vancouver

Galinelli NC, Bamford NJ, Erdody ML, Mackenzie SA, Warnken T, Harris PA, et al. Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction. Equine Veterinary Journal. 2025;57(6):1612-1622. doi:10.1111/evj.14468

BibTeX
@article{Galinelli2025,
  author = {Galinelli, Nicolas C and Bamford, Nicholas J and Erdody, Madison L and Mackenzie, Skye A and Warnken, Tobias and Harris, Patricia A and Sillence, Martin N and Bailey, Simon R},
  title = {Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction},
  journal = {Equine Veterinary Journal},
  year = {2025},
  volume = {57},
  number = {6},
  pages = {1612--1622},
  doi = {10.1111/evj.14468}
}
Kostenlos starten →